Grandfield & Dodd LLC Has $2.90 Million Holdings in Regeneron Pharmaceuticals Inc (REGN)

Grandfield & Dodd LLC boosted its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 22.7% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,173 shares of the biopharmaceutical company’s stock after acquiring an additional 1,327 shares during the period. Grandfield & Dodd LLC’s holdings in Regeneron Pharmaceuticals were worth $2,898,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Janus Henderson Group PLC boosted its holdings in shares of Regeneron Pharmaceuticals by 12.7% in the 2nd quarter. Janus Henderson Group PLC now owns 1,802,740 shares of the biopharmaceutical company’s stock valued at $621,927,000 after buying an additional 203,306 shares in the last quarter. Polen Capital Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 4.5% in the 2nd quarter. Polen Capital Management LLC now owns 1,483,634 shares of the biopharmaceutical company’s stock valued at $511,839,000 after buying an additional 64,493 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Regeneron Pharmaceuticals by 2.0% in the 2nd quarter. Northern Trust Corp now owns 934,245 shares of the biopharmaceutical company’s stock valued at $322,306,000 after buying an additional 17,931 shares in the last quarter. Manning & Napier Group LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 4.7% in the 2nd quarter. Manning & Napier Group LLC now owns 516,338 shares of the biopharmaceutical company’s stock valued at $178,130,000 after buying an additional 23,315 shares in the last quarter. Finally, First Trust Advisors LP boosted its holdings in shares of Regeneron Pharmaceuticals by 53.5% in the 3rd quarter. First Trust Advisors LP now owns 288,480 shares of the biopharmaceutical company’s stock valued at $116,557,000 after buying an additional 100,492 shares in the last quarter. Institutional investors own 66.06% of the company’s stock.

Several research analysts have recently issued reports on the stock. TheStreet upgraded shares of Regeneron Pharmaceuticals from a “c” rating to a “b-” rating in a report on Wednesday, July 25th. Robert W. Baird cut shares of Regeneron Pharmaceuticals from an “outperform” rating to a “neutral” rating in a report on Friday, August 3rd. BidaskClub upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, October 19th. Jefferies Financial Group restated a “hold” rating and issued a $340.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, July 24th. Finally, Canaccord Genuity upped their target price on shares of Regeneron Pharmaceuticals from $304.00 to $390.00 and gave the company a “hold” rating in a report on Friday, August 3rd. Two investment analysts have rated the stock with a sell rating, seventeen have given a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $410.95.

REGN stock opened at $354.93 on Tuesday. Regeneron Pharmaceuticals Inc has a 12 month low of $281.89 and a 12 month high of $432.50. The firm has a market capitalization of $38.10 billion, a P/E ratio of 26.47, a price-to-earnings-growth ratio of 1.18 and a beta of 1.34. The company has a quick ratio of 2.92, a current ratio of 3.62 and a debt-to-equity ratio of 0.10.

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,500 shares of the company’s stock in a transaction on Wednesday, August 22nd. The shares were sold at an average price of $380.49, for a total transaction of $570,735.00. Following the completion of the transaction, the director now owns 1,500 shares in the company, valued at approximately $570,735. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Sanofi sold 104,552 shares of the company’s stock in a transaction on Thursday, September 6th. The stock was sold at an average price of $406.68, for a total transaction of $42,519,207.36. The disclosure for this sale can be found here. In the last quarter, insiders sold 110,052 shares of company stock valued at $44,651,762. 12.42% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/11/06/grandfield-dodd-llc-has-2-90-million-holdings-in-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

See Also: Book Value Of Equity Per Share – BVPS Explained

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply